Aspirin is one From the most frequently taken drugs in the world, for decades recommended as a way of protecting against heart attacks and impacts in endangered patients. However, the fresh study revealed that Klopidogrel, another commonly used blood thinning or anticoagulant, is more effective in preventing solemn heart attacks and impact and there is no additional risk.
The discovery is the result of research conducted by an international team of scientists from the USA, Great Britain, Switzerland, Australia and Japan. Their work is a meta-analysis that collects and analyzes the results of many smaller studies in order to draw a more reliable conclusion, looking at a larger number of data. In total, this meta -analysis concerned clinical data of almost 29,000 patients who were diagnosed with coronary artery disease (CAD), a condition in which fat accumulates in arteries, which can lead to secondary effects such as heart attacks and heart failure.
Specialists conducted a systematic search for medical databases, such as Pubmed, Scopus, Web of Science and Embase to find randomized CAD treatment research published until April 12, 2025. The goal was to identify articles comparing aspirin effectiveness in comparison with clopidogrel in preventing cardiovascular death, heart attacks, heart attacks.
The analysis focused on seven studies, which included clinical information from people with confirmed cases of CAD treated with aspirin or clopidogrel for an average of 2.3 years. After observations of 5.5 years, scientists noticed that those who received Klopidogrel had a 14 % lower risk of a solemn cardiovascular event compared to those treated with aspirin.
Ultimately, the team said that these discoveries “add to evidence” that Klopidogrel is better than aspirin to prevent solemn unwanted heart and vascular events. In the opinion of scientists, these discoveries support with the support of clopidogrel over aspirin in patients with a fixed CAD to prevent them from continuing solemn complications as a result of their condition, such as a heart attack. The discoveries were published in the journal Lancet.
As for the mortality and risk of bleeding, the meta -analysis said that the indicators were similar in both groups, confirming that Klopidogrel is as secure as aspirin.
“According to our best knowledge, Klopidogrel monotherapy is the only antiplatetic treatment that consistently showed greater effectiveness than aspirin without prejudice to safety,” wrote scientists in the article.
The discovery can transform medical guidelines on the international arena. Clopidogrel is a widely available, inexpensive drug with reliable general versions, features that would make it easier to include in routine clinical practice. Nevertheless, specialists emphasize that wider tests are needed to assess the profitability of clopidogrel and its efficiency in various populations to support it in the treatment standards.
Cardiovascular diseases are the main cause of death in the world. According to the World Health Organization, estimated 17.9 million people They die of these conditions each year. Over four out of five of these deaths are caused by coronary artery disease or stroke. Novel research suggests that Clopidogrel can become a key alternative to combating this public health problem, whose occurrence is still growing all over the world.
This story originally appeared Wired in Spanish and was translated from Spanish.